Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neurocrine ( (NBIX) ) has shared an announcement.
On May 18, 2026, Neurocrine Biosciences completed its $2.9 billion cash acquisition of Soleno Therapeutics, following a tender offer that closed on May 15 with 88.9% of Soleno shares validly tendered, and subsequently merged Soleno into a wholly owned subsidiary, delisting its stock. The deal adds VYKAT XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine’s commercial lineup alongside INGREZZA and CRENESSITY, strengthening its position in endocrinology and rare disease and giving it a recently launched product with strong early adoption and significant commercial potential.
To support its balance sheet and funding flexibility around these transactions, Neurocrine entered into a five-year, $1.0 billion senior secured revolving credit facility with JPMorgan Chase and other lenders on May 14, 2026, and drew an initial $600 million, secured by substantially all of its and certain subsidiaries’ assets. The facility, which carries variable interest tied to Term SOFR or an alternate base rate and includes leverage and interest coverage covenants, provides additional liquidity headroom as Neurocrine integrates Soleno and scales the VYKAT XR launch in the rare disease market.
The most recent analyst rating on (NBIX) stock is a Buy with a $210.00 price target. To see the full list of analyst forecasts on Neurocrine stock, see the NBIX Stock Forecast page.
Spark’s Take on NBIX Stock
According to Spark, TipRanks’ AI Analyst, NBIX is a Outperform.
NBIX scores highly on financial performance (expanding profitability, strong free cash flow, and low leverage), supported by a constructive earnings update with reaffirmed guidance and strong commercial momentum. The score is tempered by technically overbought conditions and a valuation that is reasonable but not clearly discounted, with no dividend yield provided.
To see Spark’s full report on NBIX stock, click here.
More about Neurocrine
Neurocrine Biosciences is a leading biopharmaceutical company focused on discovering, developing and commercializing treatments for under-addressed neurological, psychiatric, endocrine and immunological disorders. Its portfolio includes FDA-approved therapies such as INGREZZA for tardive dyskinesia and Huntington’s chorea, CRENESSITY for classic congenital adrenal hyperplasia, and VYKAT XR for hyperphagia in Prader-Willi syndrome, alongside products for endometriosis and uterine fibroids marketed with AbbVie.
The company leverages more than three decades of neuroscience expertise to build a diversified pipeline of mid- to late-stage candidates across its core therapeutic areas, aiming to expand its presence in rare diseases and complex central nervous system conditions.
Average Trading Volume: 1,141,278
Technical Sentiment Signal: Buy
Current Market Cap: $15.93B
For detailed information about NBIX stock, go to TipRanks’ Stock Analysis page.